DIVISLAB2022-10-012022-12-31in-bse-fin:OneOperatingExpenses01Member DIVISLAB2022-10-012022-12-31in-bse-fin:FourOperatingExpenses01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares DIVISLAB 2022-04-01 2023-03-31 2023-01-23 INR Lakhs Third quarter Single segment Manufacture of Active Pharmaceutical Ingredients, intermediates and nutraceutical ingredients 2022-10-01 2022-12-31 Unaudited Standalone 16898300000.00 1163400000.00 18061700000.00 5966000000.00 0.00 1511500000.00 2328400000.00 1100000.00 865400000.00 2998200000.00 13670600000.00 4391100000.00 0.00 4391100000.00 1045800000.00 236300000.00 1282100000.00 0.00 3109000000.00 0.00 0.00 0.00 0.00 3109000000.00 6600000.00 3115600000.00 3115600000.00 0.00 530900000.00 2 11.71 11.71 0.00 0.00 11.71 11.71 1. The above Statement of standalone unaudited financial results for the quarter and nine months ended 31st December 2022, is prepared in accordance with Indian Accounting Standards (‘Ind AS’) prescribed under section 133 of the Companies Act 2013 read with the relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. The financial results were, as reviewed by the Audit Committee, considered and approved by the Board of Directors at its meeting held on 3rd February 2023. The same also were subjected to “limited review” by the Auditors of the Company and their report contains no qualification. 2. The Company is engaged in the manufacture of Active Pharmaceutical Ingredients, Intermediates and Nutraceutical Ingredients and the same constitutes a single reportable business segment as per Ind AS 108. 3. The Company does not have any discontinued operations and the Profit for the period represents the Profits from continuing operations only. 4. Forex gain included in Other Income and forex Loss included in Other Expenses for the respective periods is as given below: Rs. in lakhs Quarter ended Nine Months ended Year ended 31.12.2022 30.09.2022 31.12.2021 31.12.2022 31.12.2021 31.03.2022 Forex gain/(loss) 4874 3000 (362) 13674 869 3798 Single segment 2022-04-01 2022-12-31 Unaudited Standalone 57171300000.00 2855800000.00 60027100000.00 21868400000.00 0.00 274300000.00 7011100000.00 3400000.00 2554400000.00 9454900000.00 41166500000.00 18860600000.00 0.00 18860600000.00 3320700000.00 646300000.00 3967000000.00 0.00 14893600000.00 0.00 0.00 0.00 0.00 14893600000.00 19700000.00 14913300000.00 14913300000.00 0.00 530900000.00 2 56.10 56.10 0.00 0.00 56.10 56.10 Other expenses 2998200000.00 Other expenses 9454900000.00